Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

Abstract Background Camrelizumab (a PD-1 inhibitor) has been used as a potential therapy in unresectable advanced esophageal squamous cell carcinoma (ESCC) along with adjuvant treatment in locally advanced ESCC, exhibiting an acceptable efficacy and safety profile. This pilot study was designed to f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peng Yang, Xiao Zhou, Xuefeng Yang, Yuefeng Wang, Tao Sun, Shiying Feng, Xianyou Ma
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Camrelizumab Chemotherapy Neoadjuvant therapy Esophageal squamous cell carcinoma Efficacy and safety Surgery RD1-811 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2edb38899a1f463695926b3d0812ce34
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2edb38899a1f463695926b3d0812ce34
record_format	dspace
spelling	oai:doaj.org-article:2edb38899a1f463695926b3d0812ce342021-11-28T12:30:41ZNeoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study10.1186/s12957-021-02446-51477-7819https://doaj.org/article/2edb38899a1f463695926b3d0812ce342021-11-01T00:00:00Zhttps://doi.org/10.1186/s12957-021-02446-5https://doaj.org/toc/1477-7819Abstract Background Camrelizumab (a PD-1 inhibitor) has been used as a potential therapy in unresectable advanced esophageal squamous cell carcinoma (ESCC) along with adjuvant treatment in locally advanced ESCC, exhibiting an acceptable efficacy and safety profile. This pilot study was designed to further investigate the clinical value and tolerance of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC. Methods A total of 16 patients with locally advanced ESCC were recruited. Patients received 2 cycles of neoadjuvant therapy including 2 doses of camrelizumab concurrent with 2 cycles of paclitaxel plus carboplatin followed by surgery 4 weeks afterward. Then, the treatment response after neoadjuvant therapy, R0 resection rate, tumor regression grade (TRG), and pathological complete remission (pCR) rate were measured. Besides, adverse events were documented. At last, progression-free survival (PFS) and overall survival (OS) were assessed. Results Generally, objective remission rate (ORR) was 81.3% whereas disease control rate (DCR) was 100% after neoadjuvant therapy. Concerning TRG grade, 31.3, 37.5, 18.8, and 12.5% patients reached TRG0, TRG1, TRG2, and TRG3, respectively. Then, pCR rate and R0 resection rate were 31.3 and 93.8%, respectively. Besides, mean PFS and OS were 18.3 months (95%CI: (16.2–20.5) months) and 19.2 months (95%CI: (17.7–20.7) months), respectively, with a 1-year PFS of 83% and OS of 90.9%. Adverse events included white blood cell decrease (37.5%), neutrophil decrease (31.3%), reactive cutaneous capillary endothelial proliferation (37.5%), and nausea or vomiting (25.0%), which were relatively mild and manageable. Conclusion Neoadjuvant camrelizumab plus chemotherapy exhibits good efficacy and acceptable tolerance in patients with locally advanced ESCC.Peng YangXiao ZhouXuefeng YangYuefeng WangTao SunShiying FengXianyou MaBMCarticleCamrelizumabChemotherapyNeoadjuvant therapyEsophageal squamous cell carcinomaEfficacy and safetySurgeryRD1-811Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENWorld Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Camrelizumab Chemotherapy Neoadjuvant therapy Esophageal squamous cell carcinoma Efficacy and safety Surgery RD1-811 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Camrelizumab Chemotherapy Neoadjuvant therapy Esophageal squamous cell carcinoma Efficacy and safety Surgery RD1-811 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Peng Yang Xiao Zhou Xuefeng Yang Yuefeng Wang Tao Sun Shiying Feng Xianyou Ma Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
description	Abstract Background Camrelizumab (a PD-1 inhibitor) has been used as a potential therapy in unresectable advanced esophageal squamous cell carcinoma (ESCC) along with adjuvant treatment in locally advanced ESCC, exhibiting an acceptable efficacy and safety profile. This pilot study was designed to further investigate the clinical value and tolerance of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC. Methods A total of 16 patients with locally advanced ESCC were recruited. Patients received 2 cycles of neoadjuvant therapy including 2 doses of camrelizumab concurrent with 2 cycles of paclitaxel plus carboplatin followed by surgery 4 weeks afterward. Then, the treatment response after neoadjuvant therapy, R0 resection rate, tumor regression grade (TRG), and pathological complete remission (pCR) rate were measured. Besides, adverse events were documented. At last, progression-free survival (PFS) and overall survival (OS) were assessed. Results Generally, objective remission rate (ORR) was 81.3% whereas disease control rate (DCR) was 100% after neoadjuvant therapy. Concerning TRG grade, 31.3, 37.5, 18.8, and 12.5% patients reached TRG0, TRG1, TRG2, and TRG3, respectively. Then, pCR rate and R0 resection rate were 31.3 and 93.8%, respectively. Besides, mean PFS and OS were 18.3 months (95%CI: (16.2–20.5) months) and 19.2 months (95%CI: (17.7–20.7) months), respectively, with a 1-year PFS of 83% and OS of 90.9%. Adverse events included white blood cell decrease (37.5%), neutrophil decrease (31.3%), reactive cutaneous capillary endothelial proliferation (37.5%), and nausea or vomiting (25.0%), which were relatively mild and manageable. Conclusion Neoadjuvant camrelizumab plus chemotherapy exhibits good efficacy and acceptable tolerance in patients with locally advanced ESCC.
format	article
author	Peng Yang Xiao Zhou Xuefeng Yang Yuefeng Wang Tao Sun Shiying Feng Xianyou Ma
author_facet	Peng Yang Xiao Zhou Xuefeng Yang Yuefeng Wang Tao Sun Shiying Feng Xianyou Ma
author_sort	Peng Yang
title	Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
title_short	Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
title_full	Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
title_fullStr	Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
title_full_unstemmed	Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
title_sort	neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/2edb38899a1f463695926b3d0812ce34
work_keys_str_mv	AT pengyang neoadjuvantcamrelizumabpluschemotherapyintreatinglocallyadvancedesophagealsquamouscellcarcinomapatientsapilotstudy AT xiaozhou neoadjuvantcamrelizumabpluschemotherapyintreatinglocallyadvancedesophagealsquamouscellcarcinomapatientsapilotstudy AT xuefengyang neoadjuvantcamrelizumabpluschemotherapyintreatinglocallyadvancedesophagealsquamouscellcarcinomapatientsapilotstudy AT yuefengwang neoadjuvantcamrelizumabpluschemotherapyintreatinglocallyadvancedesophagealsquamouscellcarcinomapatientsapilotstudy AT taosun neoadjuvantcamrelizumabpluschemotherapyintreatinglocallyadvancedesophagealsquamouscellcarcinomapatientsapilotstudy AT shiyingfeng neoadjuvantcamrelizumabpluschemotherapyintreatinglocallyadvancedesophagealsquamouscellcarcinomapatientsapilotstudy AT xianyouma neoadjuvantcamrelizumabpluschemotherapyintreatinglocallyadvancedesophagealsquamouscellcarcinomapatientsapilotstudy
_version_	1718407941903613952

Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

Ejemplares similares